[Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].

Tumour necrosis factor (TNF) a has been identified through basic research as a molecule that has a central role in the regulation of many autoimmune chronic inflammatory diseases. Experimental and clinical research with TNF antagonists has validated this observation. At this time, TNF blockade is indicated for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis. Recent clinical study with this type of molecularly targeted intervention has determined that chronic inflammatory diseases can share some pathophysiological mechanisms, while others are more specific for certain diseases. Therefore, TNF appears to play a central role in multiple forms of inflammation, but the underlying pathogenic mechanism remains intact during TNF blockade. For this reason, there is much interest in studies of combination therapy in which TNF antagonists are added to other treatments, such as methotrexate. Anti-TNF therapy is expensive; therefore, treatment strategies are needed that are affordable and provide optimal care for groups of patients that do not adequately respond to conventional therapy.